IL319503A - PEGylated liposomes and methods of use - Google Patents

PEGylated liposomes and methods of use

Info

Publication number
IL319503A
IL319503A IL319503A IL31950325A IL319503A IL 319503 A IL319503 A IL 319503A IL 319503 A IL319503 A IL 319503A IL 31950325 A IL31950325 A IL 31950325A IL 319503 A IL319503 A IL 319503A
Authority
IL
Israel
Prior art keywords
methods
pegylated liposomes
pegylated
liposomes
Prior art date
Application number
IL319503A
Other languages
English (en)
Hebrew (he)
Original Assignee
Access To Advanced Health Inst
Univ Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access To Advanced Health Inst, Univ Virginia Patent Foundation filed Critical Access To Advanced Health Inst
Publication of IL319503A publication Critical patent/IL319503A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319503A 2016-05-16 2017-05-15 PEGylated liposomes and methods of use IL319503A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662337328P 2016-05-16 2016-05-16
PCT/US2017/032756 WO2017200957A1 (en) 2016-05-16 2017-05-15 Pegylated liposomes and methods of use

Publications (1)

Publication Number Publication Date
IL319503A true IL319503A (en) 2025-05-01

Family

ID=58794159

Family Applications (3)

Application Number Title Priority Date Filing Date
IL319503A IL319503A (en) 2016-05-16 2017-05-15 PEGylated liposomes and methods of use
IL263030A IL263030B2 (en) 2016-05-16 2017-05-15 Pegylated liposomes and methods of use
IL313085A IL313085B2 (en) 2016-05-16 2017-05-15 Pegylated liposomes and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL263030A IL263030B2 (en) 2016-05-16 2017-05-15 Pegylated liposomes and methods of use
IL313085A IL313085B2 (en) 2016-05-16 2017-05-15 Pegylated liposomes and methods of use

Country Status (12)

Country Link
US (3) US11266602B2 (enExample)
EP (1) EP3458028A1 (enExample)
JP (2) JP7195147B2 (enExample)
KR (1) KR102483033B1 (enExample)
CN (1) CN109562057A (enExample)
AU (2) AU2017268175B2 (enExample)
BR (1) BR112018073676B1 (enExample)
CA (1) CA3023672A1 (enExample)
IL (3) IL319503A (enExample)
MX (1) MX2018013640A (enExample)
WO (1) WO2017200957A1 (enExample)
ZA (1) ZA201807128B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
CN107998070A (zh) * 2017-12-12 2018-05-08 南京中医药大学 一种复合磷脂传递体及其在制备经皮给药制剂中的应用
US20220339282A1 (en) * 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN112930184B (zh) * 2018-12-17 2024-07-12 卫材R&D管理有限公司 包含脂质体的配制品
CN110151702A (zh) * 2019-06-24 2019-08-23 昆明医科大学 聚乙二醇修饰流感疫苗脂质体及其制备方法
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
KR102328531B1 (ko) * 2020-01-23 2021-11-17 서울대학교산학협력단 체내 면역 세포 표적 황화수소 공여체 담지 리포좀을 포함하는 면역질환 치료 또는 예방용 약학 조성물
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
JP2023535405A (ja) * 2020-07-22 2023-08-17 ユニバーシティー オブ ヒューストン システム 呼吸器疾患に関連する状態の処置および防止
EP4048308A1 (en) 2020-12-23 2022-08-31 Infectious Disease Research Institute Solanesol vaccine adjuvants and methods of preparing same
WO2022183120A1 (en) * 2021-02-26 2022-09-01 University Of Virginia Patent Foundation Development of covid-19 vaccine using a dual tlr ligand liposome adjuvant
EP4304567A1 (en) * 2021-03-11 2024-01-17 The Trustees of the University of Pennsylvania Targeted therapeutic lipid nanoparticles and methods of use
KR102682082B1 (ko) * 2021-06-01 2024-07-05 서울대학교산학협력단 리포좀 및 이를 포함하는 암 방사선 치료용 약학 조성물
AU2022348995A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535351A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション 乾燥ナノ粒子組成物
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
EP4637712A1 (en) * 2022-12-19 2025-10-29 Newimmune II, LLC Nanoparticulate formulation
CN115737800B (zh) * 2023-01-09 2023-05-23 江苏瑞科生物技术股份有限公司 一种复合脂质体佐剂及其制备方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
EP0449856B1 (en) 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
DE122007000085I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Polynukleotidabschnitt des HPV16-Genoms
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
ATE177755T1 (de) 1991-11-16 1999-04-15 Smithkline Beecham Biolog Hybrides protein zwischen cs aus plasmodium und hbsag
DE122007000101I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
PT688227E (pt) 1993-03-09 2005-10-31 Univ Rochester Producao de proteina da capsula de papiloma humano e particulas semelhantes a virus
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
DE69433696T2 (de) 1993-11-02 2004-08-12 Matsushita Electric Industrial Co., Ltd., Kadoma Halbleiterbauelement mit einem Aggregat von Mikro-Nadeln aus Halbleitermaterial
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
DK0809700T3 (da) 1994-10-07 2006-09-18 Univ Loyola Chicago Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
BR9807734A (pt) 1997-02-25 2000-10-31 Corixa Corp Composto para imunodiagnose de câncer de próstata e métodos para o uso dos memos
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
SI1053325T1 (sl) 1998-02-05 2006-06-30 Glaxosmithkline Biolog Sa S tumorjem povezani antigenski derivati iz MAGE druzine in sekvence nukleinske kisline, ki jih kodirajo, uporabljeni za pripravo fuzijskih proteinov in sestavkov za vakcinacijo
IL138809A0 (en) 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
AU2004315876B2 (en) 2003-10-03 2011-05-26 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
DE102005032175A1 (de) 2005-07-09 2007-01-18 Krones Ag Behälter-Behandlungsmaschine und Verfahren zum Laden und Entladen einer Behälter-Behandlungsmaschine
DE502005002538D1 (de) 2005-07-19 2008-03-06 Holzapfel Gmbh & Co Kg Geb Auftriebshilfe
US9333250B2 (en) * 2006-04-06 2016-05-10 The Johns Hopkins University Methods and compositions for treating bacterial infection
LT2484375T (lt) * 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
EA019151B1 (ru) * 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
US8793881B2 (en) 2008-08-15 2014-08-05 Stanley Black & Decker, Inc. Utility knife with blade lock
EP2328613A1 (en) * 2008-08-28 2011-06-08 GlaxoSmithKline Biologicals S.A. Vaccine
SG2014014385A (en) * 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
WO2010143971A2 (en) * 2009-06-08 2010-12-16 Epitarget As Lipophilic drug carrier
TWI397428B (zh) * 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
US20120014866A1 (en) 2010-07-15 2012-01-19 Ivor Bull Copper Containing ZSM-34, OFF And/Or ERI Zeolitic Material For Selective Reduction Of NOx
RS55819B1 (sr) 2010-08-17 2017-08-31 3M Innovative Properties Co Kompozicije sa lipidiranim modifikatorom imuno-odgovora, formulacije, i postupci
PL4066857T3 (pl) * 2010-08-31 2023-03-20 Glaxosmithkline Biologicals Sa Pegylowane liposomy do dostarczania rna kodującego immunogen
CN103998058B (zh) * 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
KR20140097215A (ko) 2011-10-31 2014-08-06 말린크로트 엘엘씨 암 치료를 위한 조합 리포좀 조성물
EP2787977A4 (en) * 2011-12-09 2015-05-06 Univ California LIPOSOMAL ACTIVE INVERTING
EP2811981B1 (en) * 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
PL2836234T3 (pl) * 2012-04-12 2020-02-28 Yale University Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych
CA2876143A1 (en) 2012-06-13 2013-12-19 Incytu, Inc. Compositions, methods and devices for activating an immune response
US10722569B2 (en) * 2012-07-05 2020-07-28 Children's Medical Center Corporation Bacterial biofilm matrix as a platform for protein delivery
WO2014018737A1 (en) 2012-07-26 2014-01-30 National Oilwell Varco L.P. Telescoping core barrel
US8638146B1 (en) 2012-07-31 2014-01-28 Cambridge Silicon Radio Limited Dual mode phase detection
EP2968142A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Liposomal cisplatin compositions for cancer therapy
MX375123B (es) * 2014-02-14 2025-03-06 Immune Design Corp Composición para usarse en mejorar la respuesta inmune contra el cáncer.
EP3116479A1 (en) * 2014-03-12 2017-01-18 GlaxoSmithKline Biologicals S.A. Liposomal compositions for mucosal delivery
CN105534908B (zh) * 2016-01-15 2018-12-14 徐州医学院 一种包载核酸药物的具缺氧响应能力和放疗增敏功能脂质体
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use

Also Published As

Publication number Publication date
MX2018013640A (es) 2019-08-01
IL263030B2 (en) 2024-11-01
IL313085B1 (en) 2025-04-01
KR20190025822A (ko) 2019-03-12
IL313085A (en) 2024-07-01
CN109562057A (zh) 2019-04-02
AU2017268175B2 (en) 2023-02-23
AU2023200515B2 (en) 2024-04-18
ZA201807128B (en) 2019-06-26
KR102483033B1 (ko) 2022-12-30
US11266602B2 (en) 2022-03-08
WO2017200957A1 (en) 2017-11-23
US20220160632A1 (en) 2022-05-26
US12318484B2 (en) 2025-06-03
JP2022177112A (ja) 2022-11-30
JP7195147B2 (ja) 2022-12-23
IL313085B2 (en) 2025-08-01
IL263030A (en) 2018-12-31
IL263030B1 (en) 2024-07-01
EP3458028A1 (en) 2019-03-27
JP2019518739A (ja) 2019-07-04
US20250241857A1 (en) 2025-07-31
AU2023200515A1 (en) 2023-03-02
RU2018137866A (ru) 2020-06-17
AU2017268175A1 (en) 2018-11-15
BR112018073676A2 (pt) 2019-02-26
BR112018073676B1 (pt) 2023-10-03
US20200138715A1 (en) 2020-05-07
RU2018137866A3 (enExample) 2021-02-04
CA3023672A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
ZA201807128B (en) Pegylated liposomes and methods of use
IL286316A (en) New micro-dystrophins and related method of use
IL287140A (en) A process for the preparation of polyethylene glycol-converted pharmaceutical binders and their intermediates
IL255801A (en) Liposomal nanoconstructs and methods of making and using the same
ZA201807519B (en) Liposomal preparation and methods of treatment
IL250415B (en) Antibodies against pd-l and methods of using them
PL3548033T3 (pl) Związki i sposoby ich stosowania
GB2539350B (en) Amyloid targeting agents and methods of using the same
IL282482A (en) Variants of protoxin-II and methods of use
IL265881A (en) Inhaler and methods of use thereof
IL256515A (en) Therapeutic peptides and methods of use thereof
ZA201802329B (en) Hppd variants and methods of use
IL282508A (en) Variants of protoxin-II and methods of use
IL255565A (en) Substituted benzamides and methods of use thereof
IL265955A (en) Therapeutic compounds and methods of using them
PL3510159T3 (pl) Geny pestycydowe i sposoby stosowania
PT3397364T (pt) Elementos estruturados e métodos de utilização
IL258429A (en) Portable spinner and methods of use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
IL252508A0 (en) Oxidized lipids and their uses
PL3442560T3 (pl) Formulacje oksytocyny zawierające magnez i sposoby zastosowania
IL247448A0 (en) Peptides and methods of use
GB201509977D0 (en) Dispensers and methods of use thereof
AU201614688S (en) Alu sling sofa of two seaters
AU201614706S (en) Alu sofa of three seaters